184 related articles for article (PubMed ID: 37979138)
1. Considerations and limitations of buprenorphine prescribing for opioid use disorder in the intensive care unit setting: A narrative review.
Erstad BL; Glenn MJ
Am J Health Syst Pharm; 2024 Mar; 81(6):171-182. PubMed ID: 37979138
[TBL] [Abstract][Full Text] [Related]
2. Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.
Szczesniak L; Britton S; Rn TB; Sullivan R
Harm Reduct J; 2024 Jun; 21(1):114. PubMed ID: 38849912
[TBL] [Abstract][Full Text] [Related]
3. Pain Management Considerations in Patients With Opioid Use Disorder Requiring Critical Care.
Smith K; Wang M; Abdukalikov R; McAullife A; Whitesell D; Richard J; Sauer W; Quaye A
J Clin Pharmacol; 2022 Apr; 62(4):449-462. PubMed ID: 34775634
[TBL] [Abstract][Full Text] [Related]
4. Medications for opioid use disorder prescribed at hospital discharge associated with decreased opioid agonist dispensing in patients with opioid use disorder requiring critical care: A retrospective study.
Quaye A; Wampole C; Riker RR; Seder DB; Sauer WJ; Richard J; Craig W; Gagnon DJ
J Subst Use Addict Treat; 2023 Dec; 155():209176. PubMed ID: 37778703
[TBL] [Abstract][Full Text] [Related]
5. Management of Critically Ill Patients Receiving Medications for Opioid Use Disorder.
Erstad BL; Glenn MJ
Chest; 2024 Feb; 165(2):356-367. PubMed ID: 37898187
[TBL] [Abstract][Full Text] [Related]
6. Practices and Outcomes Associated With Sublingual Buprenorphine Use in a Critically Ill Population.
Vanini DJ; Corvelli JM; Maynard KM; Rappaport SH; Grasso G; Jones R; Acquisto NM; Schult RF
Crit Care Explor; 2024 Mar; 6(3):e1062. PubMed ID: 38481543
[TBL] [Abstract][Full Text] [Related]
7. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Carswell N; Angermaier G; Castaneda C; Delgado F
Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
[TBL] [Abstract][Full Text] [Related]
8. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
10. A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions.
Pourmand A; Beisenova K; Shukur N; Tebo C; Mortimer N; Mazer-Amirshahi M
Am J Emerg Med; 2021 Oct; 48():316-322. PubMed ID: 34274576
[TBL] [Abstract][Full Text] [Related]
11. A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder.
Miller JC; Brooks MA; Wurzel KE; Cox EJ; Wurzel JF
Drugs R D; 2023 Dec; 23(4):339-362. PubMed ID: 37938531
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine Microdosing Cross Tapers: A Time for Change.
Raheemullah A; Benhamou OM; Kuo J; Lembke A
Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554317
[TBL] [Abstract][Full Text] [Related]
13. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
14. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
Cisewski DH; Santos C; Koyfman A; Long B
Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
[TBL] [Abstract][Full Text] [Related]
15. Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: Titration, implementation barriers, and strategies to overcomes.
DeWeese JP; Krenz JR; Wakeman SE; Peckham AM
Subst Abus; 2021; 42(4):506-511. PubMed ID: 33945452
[No Abstract] [Full Text] [Related]
16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
17. How Do I Manage Acute Pain for Patients Prescribed Buprenorphine for Opioid Use Disorder?
Sandhu S; Calcaterra SL
NEJM Evid; 2024 May; 3(5):EVIDccon2300275. PubMed ID: 38815158
[TBL] [Abstract][Full Text] [Related]
18. Medicolegal Considerations in the Management of Opioid Use Disorder With Buprenorphine in the Correctional Setting.
Mitchell M
J Correct Health Care; 2021 Sep; 27(3):210-214. PubMed ID: 34388040
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine Prescribing and Dosing Limits: Evidence and Policy Goals.
Coyle DT; Stewart S; Bortz C; Manalo J; Ritvo A; Krsak M
Subst Abus; 2023; 44(1):17-23. PubMed ID: 37226901
[TBL] [Abstract][Full Text] [Related]
20. Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study.
Baumgartner K; Salmo E; Liss D; Devgun J; Mullins M; Galati B; Kelly J; Schwarz E
Clin Toxicol (Phila); 2022 Jun; 60(6):688-693. PubMed ID: 35048759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
